Skip to main content
Manisha Shah, MD, Oncology, Columbus, OH, Ohio State University Wexner Medical Center

ManishaH.ShahMD

Oncology • Columbus, OH

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shah's full profile

Already have an account?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1997
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1992 - 1995
  • N.H.L Municipal Medical College
    N.H.L Municipal Medical CollegeClass of 1990

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1997 - 2026

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of Selpercatinib in RET-Altered Thyroid Cancers  
    Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
  • Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors  
    Neil Saunders, David Strosberg, Jill Onesti, Carl R Schmidt, Manisha Shah, Mary Dillhoff, Lawrence A Shirley, Bhavana Konda, Annals of Surgical Oncology

Authored Content

  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
  • Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
  • Join now to see all

Press Mentions

  • Cabozantinib Active as Salvage Therapy in Thyroid Cancer
    Cabozantinib Active as Salvage Therapy in Thyroid CancerSeptember 5th, 2017
  • Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer
    Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid CancerJune 5th, 2017
  • Novel Agents Improve MCL Care, Tumor Profiling Key to Further Advances
    Novel Agents Improve MCL Care, Tumor Profiling Key to Further AdvancesOctober 21st, 2015
  • Join now to see all

Grant Support

  • Targeting RAF And VEGF Signaling In Thyroid CancerNational Cancer Institute2005–2006
  • Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2002–2004

Hospital Affiliations

Dr. Manisha Shah, Dr. Manisha Shah, MD, Dr. M Shah, Dr. Manisha H. Shah